Asia Pacific Influenza Treatment Market By Drug Class (Anti-Viral Drugs, Interferons, Vaccines), By Route of Administration (Oral, Parenteral, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others), and Country  

Purchase Option

$ 3100
$ 4600
$ 6900

Asia Pacific Influenza Treatment Market size was valued at USD 2,963.1 million in 2022, growing at a CAGR of 7.1% during the forecast period 2023-29 . The global market provides a detailed overview and which can be segmented by drug class, route of administration, and distribution channel. By drug class, the Asia Pacific influenza treatment market has been segmented into anti-viral drugs, interferons, and vaccines. By drug class, the vaccines segment held the largest revenue share of the Asia Pacific influenza treatment market in past years and is expected to have the fastest growth rate over the forecasted period due to the increasing demand for vaccines among a large mass population due to increasing incidences of influenza diseases. By route of administration, the Asia Pacific influenza treatment market has been segmented into oral, parenteral, and others. By route of administration, the oral segment held the largest revenue share market in the past few years and is projected to have the fastest growth rate over the forecasted period due to easy accessibility, and minimum pain.Based on the distribution channel, the segment has been segregated into hospital pharmacies, retail pharmacies, and others. The retail pharmacy segment gained the largest market share in 2022, owing to factors such as the rise in the number of retail pharmacies across the globe. Additionally, some other factors such as a rise in awareness related to the use of influenza drugs further contribute to the growth of the market. Furthermore, the easy availability of influenza drugs surges in the number of retail pharmacies across the globe which further helps to expand the market globally.

The Asia Pacific Influenza Treatment Market Key Development:

  • In April 2021, Sanofi invested in a leading-edge production site in Singapore; continues to strengthen its vaccine manufacturing capacities.

Asia Pacific Influenza Treatment Market Dynamics

Rising incidences of influenza, increasing awareness, and requirement for new drugs and treatment amid the COVID-19 pandemic. Furthermore, a surge in healthcare expenditure and a rise in R&D investments related to ant-viral drugs boost the influenza treatment market growth. For instance, in 2018, F. Hoffmann-La Roche AG launched Xofluza (Baloxavir Marboxil) for the treatment of influenza.

Asia Pacific Influenza Treatment Market Segmentation

By Drug Class
  • Anti-viral drugs
  • Zanamivir
  • Oseltamivir
  • Amantadine
  • Rimantadine
  • Others
  • Interferons
  • Vaccines
  • Trivalent
  • Quadrivalent
By Route Administration
By Distribution Channel
  • Hospital pharmacies
  • Retail pharmacies
  • Others

Frequently Asked Questions

The global Asia Pacific influenza treatment market size is expected to grow at a CAGR of 7.1% during the forecast period 2022 to 2028.

New product launches, and rising research and development activities for the treatment of influenza diseases with reasonable cost.

Investment and acquisition are the two key strategies opted for by the leading players in the market.

The major factors driving the market growth are the rising incidence of influenza cases among a large mass of the population.

Key Features of the Reports

  • The Asia Pacific Influenza Treatment Market report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitors overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup's details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter's Five Force Analysis in addition to recent technology advancements and innovations in the market
1.Executive Summary
2. Asia Pacific Influenza Treatment Market Introduction 
2.1. Asia Pacific Influenza Treatment Market  - Taxonomy
2.2. Asia Pacific Influenza Treatment Market  - Definitions
2.2.1.Drug Class
2.2.2.Route Administration
2.2.3.Distribution Channel
2.2.4.Country
3. Asia Pacific Influenza Treatment Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4. Asia Pacific Influenza Treatment Market Analysis, 2018-2022 and Forecast 2023-2029
4.1.  Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5. Asia Pacific Influenza Treatment Market  By Drug Class, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
5.1. Anti-viral drugs
5.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Zanamivir
5.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Oseltamivir
5.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. Amantadine
5.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
5.5. Rimantadine
5.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.5.3. Market Opportunity Analysis 
5.6. Others
5.6.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.6.3. Market Opportunity Analysis 
5.7. Interferons
5.7.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.7.3. Market Opportunity Analysis 
5.8. Vaccines
5.8.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.8.3. Market Opportunity Analysis 
5.9. Trivalent
5.9.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.9.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.9.3. Market Opportunity Analysis 
5.10. Quadrivalent
5.10.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.10.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.10.3. Market Opportunity Analysis 
6. Asia Pacific Influenza Treatment Market  By Route Administration, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
6.1. Oral
6.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Anti-viral drugs
6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Parenteral
6.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
6.4. Interferon alfa-2b
6.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.4.3. Market Opportunity Analysis 
6.5. Others
6.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.5.3. Market Opportunity Analysis 
7. Asia Pacific Influenza Treatment Market  By Distribution Channel, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
7.1. Hospital pharmacies
7.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Retail pharmacies
7.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Others
7.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
8. Asia Pacific Influenza Treatment Market  By Country, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
8.1. China
8.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. India
8.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Australia and New Zealand (ANZ)
8.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Japan
8.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
8.5. Rest of APAC
8.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.5.3. Market Opportunity Analysis 
9.China Influenza Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
9.1. Drug Class Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.Anti-viral drugs
9.1.2.Zanamivir
9.1.3.Oseltamivir
9.1.4.Amantadine
9.1.5.Rimantadine
9.1.6.Others
9.1.7.Interferons
9.1.8.Vaccines
9.1.9.Trivalent
9.1.10.Quadrivalent
9.2.  Route Administration Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Oral
9.2.2.Anti-viral drugs
9.2.3.Parenteral
9.2.4.Interferon alfa-2b
9.2.5.Others
9.3.  Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Hospital pharmacies
9.3.2.Retail pharmacies
9.3.3.Others
10.India Influenza Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
10.1. Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Anti-viral drugs
10.1.2.Zanamivir
10.1.3.Oseltamivir
10.1.4.Amantadine
10.1.5.Rimantadine
10.1.6.Others
10.1.7.Interferons
10.1.8.Vaccines
10.1.9.Trivalent
10.1.10.Quadrivalent
10.2.  Route Administration Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Oral
10.2.2.Anti-viral drugs
10.2.3.Parenteral
10.2.4.Interferon alfa-2b
10.2.5.Others
10.3.  Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Hospital pharmacies
10.3.2.Retail pharmacies
10.3.3.Others
11.Australia and New Zealand (ANZ) Influenza Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
11.1. Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Anti-viral drugs
11.1.2.Zanamivir
11.1.3.Oseltamivir
11.1.4.Amantadine
11.1.5.Rimantadine
11.1.6.Others
11.1.7.Interferons
11.1.8.Vaccines
11.1.9.Trivalent
11.1.10.Quadrivalent
11.2.  Route Administration Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Oral
11.2.2.Anti-viral drugs
11.2.3.Parenteral
11.2.4.Interferon alfa-2b
11.2.5.Others
11.3.  Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Hospital pharmacies
11.3.2.Retail pharmacies
11.3.3.Others
12.Japan Influenza Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
12.1. Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Anti-viral drugs
12.1.2.Zanamivir
12.1.3.Oseltamivir
12.1.4.Amantadine
12.1.5.Rimantadine
12.1.6.Others
12.1.7.Interferons
12.1.8.Vaccines
12.1.9.Trivalent
12.1.10.Quadrivalent
12.2.  Route Administration Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Oral
12.2.2.Anti-viral drugs
12.2.3.Parenteral
12.2.4.Interferon alfa-2b
12.2.5.Others
12.3.  Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Hospital pharmacies
12.3.2.Retail pharmacies
12.3.3.Others
13.Rest of APAC Influenza Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
13.1. Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Anti-viral drugs
13.1.2.Zanamivir
13.1.3.Oseltamivir
13.1.4.Amantadine
13.1.5.Rimantadine
13.1.6.Others
13.1.7.Interferons
13.1.8.Vaccines
13.1.9.Trivalent
13.1.10.Quadrivalent
13.2.  Route Administration Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Oral
13.2.2.Anti-viral drugs
13.2.3.Parenteral
13.2.4.Interferon alfa-2b
13.2.5.Others
13.3.  Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Hospital pharmacies
13.3.2.Retail pharmacies
13.3.3.Others
14. Competition Landscape
14.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
14.2.1.AstraZeneca
14.2.2.Hoffmann-La Roche
14.2.3.GlaxoSmithKline Plc.
14.2.4.Novartis AG
14.2.5.Sanofi Pasture
14.2.6.Protein Sciences Corporation
14.2.7.Emergent Biosolutions
14.2.8.BioCryst Pharmaceuticals.Inc.
14.2.9.Shionogi Inc.
14.2.10.Abbott Laboratories Inc.
15. Research Methodology 
16. Appendix and Abbreviations 
  • AstraZeneca
  • Hoffmann-La Roche
  • GlaxoSmithKline Plc.
  • Novartis AG
  • Sanofi Pasture
  • Protein Sciences Corporation
  • Emergent Biosolutions
  • BioCryst Pharmaceuticals.Inc.
  • Shionogi Inc.
  • Abbott Laboratories Inc.

Adjacent Markets